Indication: Non-Hodgkin's Lymphoma

A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibodyradionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

Relapsed non-Hodgkins B-cell lymphoma (iNHL)

Sub-indication: PART A:follicular, marginal zone, SLL, mantle cell lymphoma; PART B: follicular lymphoma

Line of Therapy: third line

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Nordic Nanovector

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.